👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 97/100
Accepting new patients
Dr
Dr Tim Robinson
Oncology
English
6,120+
Patients seen
4
Years in practice
4
Publications
1
Languages spoken
About
Dr Tim Robinson is a Consultant Senior Lecturer in Medical Oncology at the University of Bristol and an Honorary Consultant Medical Oncologist at University Hospitals Bristol and Weston NHS Foundation Trust, specialising in breast cancer. He practices across all areas of breast oncology, with particular expertise in younger women with breast cancer, management of treatment side effects, antibody drug conjugates including HER2-low disease, molecular testing and triple negative breast cancer (TNBC). He treats patients privately at GenesisCare in Bristol but also offers home chemotherapy through Sciensus.
Dr Robinson is committed to delivering highly personalised, evidence-based care and supporting patients in making informed decisions about their treatment options. He is known for dedicating significant time to each patient and for clear communication, with follow-up appointments lasting a minimum of 30 minutes and new or second-opinion consultations typically 60 minutes, ensuring comprehensive discussion and shared decision-making.
He regularly delivers educational talks for charities such as Breast Cancer Now, helping patients better understand treatment options for both metastatic breast cancer and TNBC.
Dr Robinson completed his clinical and academic training in medical oncology in Bristol and undertook a Cancer Research UK Clinical Fellowship, leading to the award of a PhD from Cardiff University. His doctoral research focused on breast cancer stem cells in chemo-resistance and the development of novel therapeutic strategies. He also holds a postgraduate diploma in oncology from the Institute of Cancer Research, University of London.
He was awarded a Coltmans Scholar Award from the San Antonio Breast Cancer Symposium for his research on the gut microbiome and breast cancer. He has authored >50 peer-reviewed publications and presented widely at national and international conferences. He is involved in multiple collaborative projects looking at the use of immunotherapy in TNBC.
Dr Robinson is actively involved in clinical research as both a Principal Investigator in Bristol and a Chief Investigator on international trials, including global Chief Investigator roles in two metastatic breast cancer studies. He is a member of national collaborative research groups and was appointed to the National Cancer Institute Breast Cancer Precision Medicine Working Group in 2022. He also serves on the NICE expert panel of breast oncologists for the breast cancer guideline committee.
Dr Robinson is committed to delivering highly personalised, evidence-based care and supporting patients in making informed decisions about their treatment options. He is known for dedicating significant time to each patient and for clear communication, with follow-up appointments lasting a minimum of 30 minutes and new or second-opinion consultations typically 60 minutes, ensuring comprehensive discussion and shared decision-making.
He regularly delivers educational talks for charities such as Breast Cancer Now, helping patients better understand treatment options for both metastatic breast cancer and TNBC.
Dr Robinson completed his clinical and academic training in medical oncology in Bristol and undertook a Cancer Research UK Clinical Fellowship, leading to the award of a PhD from Cardiff University. His doctoral research focused on breast cancer stem cells in chemo-resistance and the development of novel therapeutic strategies. He also holds a postgraduate diploma in oncology from the Institute of Cancer Research, University of London.
He was awarded a Coltmans Scholar Award from the San Antonio Breast Cancer Symposium for his research on the gut microbiome and breast cancer. He has authored >50 peer-reviewed publications and presented widely at national and international conferences. He is involved in multiple collaborative projects looking at the use of immunotherapy in TNBC.
Dr Robinson is actively involved in clinical research as both a Principal Investigator in Bristol and a Chief Investigator on international trials, including global Chief Investigator roles in two metastatic breast cancer studies. He is a member of national collaborative research groups and was appointed to the National Cancer Institute Breast Cancer Precision Medicine Working Group in 2022. He also serves on the NICE expert panel of breast oncologists for the breast cancer guideline committee.
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Tim Robinson
Education & training
-
2012–2018 MD · Medicine and Surgery
-
2018–2022 Residency · Oncology
Career & appointments
-
2022-09–2023-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
AmTrust Europe · 5,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,285 |
| Annual physical exam | 99395 | 2,075 |
| Vaccination administration | 90471 | 1,035 |
| Minor procedure (skin) | 17110 | 2,724 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 30 min | in_clinic | 720.00 EUR |
| Minor procedure (skin) | 120 min | in_clinic | 630.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 13 · i10: 9
-
Validation of clinical scoring in Oncology
DOI: 10.8341/euroclin.2026.0 · PMID: 38123998 · cited by 149
-
Long-term follow-up of Oncology across GB
DOI: 10.2023/euroclin.2025.1 · PMID: 33767258 · cited by 87
-
Validation of clinical scoring in Oncology
DOI: 10.2214/euroclin.2024.2 · PMID: 30878563 · cited by 33
-
Long-term follow-up of Oncology across GB
DOI: 10.6947/euroclin.2023.3 · PMID: 38691389 · cited by 59
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2023
- national college of family doctors — Member · since 2023
- European Union of Medical Specialists (UEMS) — Member · since 2023
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.72
- Staff Friendliness
- 4.99
- Ease Of Appointment
- 4.87
- Value For Money
- 4.89
- Would Recommend Pct
- 98
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · timothy.michael.robinson@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
